Skip to main content

Free Content Experience with rifabutin replacing rifampin in the treatment of tuberculosis

Download Article:
 Download
(PDF 272.5263671875 kb)
 
SETTING: The use of a rifamycin in anti-tuberculosis treatment regimens is crucial for shortening treatment and achieving favorable outcomes. Rifampin (RMP) is the recommended rifamycin, although adverse effects (AEs) may require its discontinuation. The use of rifabutin (RFB), a rifamycin with activity against Mycobacterium tuberculosis, in patients with an RMP-related AE has not been well studied. OBJECTIVE: To review our experience with RFB in tuberculosis (TB) treatment. METHODS: We included TB patients who received RFB in their treatment regimens from 2003 to 2009. We evaluated the indications for RFB and, if applicable, the likelihood that RMP caused an AE. We identified RMPrelated AEs associated with RFB intolerance. RESULTS: One hundred subjects were included. The indications for RFB use were RMP-related AE (57%), con- current antiretroviral therapy (21%), potential/actual interaction with other medications (14%), and as part of an alternative regimen in liver disease (8%). Nineteen patients experienced an AE while taking RFB. Among patients with a prior RMP-related AE, 80% of whom were successfully treated with RFB, only a dermatologic AE was associated with subsequent RFB intolerance. CONCLUSIONS: Our study suggests that RFB is well tol- erated by patients who develop RMP-related AEs. There may be an increased risk for RFB-related AE in patients who experienced RMP-related dermatologic events.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: ADVERSE EFFECTS; RIFABUTIN; RIFAMPIN; TUBERCULOSIS TREATMENT

Document Type: Research Article

Affiliations: 1: Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, Washington, USA 2: Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA; Tuberculosis Control Program, Public Health–Seattle & King County, Seattle, Washington, USA 3: Division of Pulmonary and Critical Care Medicine; Tuberculosis Control Program, Public Health–Seattle & King County, Seattle, Washington, USA; Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA

Publication date: 2011-11-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more